Turn Therapeutics Inc.

TTRX

NASDAQ

Healthcare

Biotechnology

Westlake Village, CA, US2 employeesturntherapeutics.com

$3.32

+0.20(6.43%)

Mkt Cap $98M

$2.71

$9.20

52-Week Range

At a Glance

AI-generated

Turn Therapeutics reported deepened GAAP operating losses of -$5.9M amid clinical development investments, partially offset by non-cash gains resulting in net loss of -$3.2M and diluted EPS of -$0.12, with cash burn reflecting ongoing R&D ramp-up.

8-K

Turn Therapeutics Inc. reported full year 2025 financial results with net loss of $3.2 million, secured up to $25 million growth capital, and provided updates on GX-03 Phase 2 trial and corporate developments.

$98M

Market Cap

—

Revenue

—

Net Income

Employees2

Fundamentals

How The Business Makes Money

Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Jan 6, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 7,

Financial Results

Mar 30, 2026

of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securiti

Material Agreement+3 More

Mar 23, 2026

of this Current Report on Form 8-K is incorporated by reference in this Item 3.02. The securities described above will be offered and sold in reliance upon an e

Regulation FD

Feb 16, 2026

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or oth

Regulation FD

Feb 8, 2026

, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act

Peer Companies

Company	Price	Change	Market Cap	P/E
IRDOpus Genetics, Inc.	$4.55	-2.99%	$324M	-57.6
GLSIGreenwich LifeSciences, I...	$22.70	-1.13%	$314M	-17.7
AGENAgenus Inc.	$3.33	-1.91%	$128M	1133.3
IKTInhibikase Therapeutics, ...	$1.79	-0.83%	$127M	-3.3
SEERSeer, Inc.	$1.71	+0.29%	$96M	-1.3
ANIXAnixa Biosciences, Inc.	$2.58	-5.15%	$87M	-8.4
HURATuHURA Biosciences, Inc.	$1.41	-13.27%	$79M	-3.4
CGTXCognition Therapeutics, I...	$0.88	-1.84%	$64M	-3.1

Company Profile

CIK0002023016

ISINUS90021W1053

CUSIP90021W105

Phone818 546 4011

Address250 N Westlake Blvd, Westlake Village, CA, 91362, US

SEC EDGAR